KIMBERLY MCCOLLEY: Open Payments
NPI 1013067016 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$864 in 47 payments from 15 companies in 2025. Trend: 2023 $224 · 2024 $525 · 2025 $864
Food & beverage: $864
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $189 |
| Lilly USA, LLC | 13 | $169 |
| Novo Nordisk Inc | 6 | $109 |
| PFIZER INC. | 3 | $70 |
| ABBVIE INC. | 3 | $70 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Merck Sharp & Dohme LLC | 1 | $20 |
Products named: MOUNJARO, PAXLOVID, Wegovy, Kerendia, REXULTI, QULIPTA, Sunosi, UBRELVY.
Industry payments across NE — which companies pay providers there.
